SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing.
A mind for precompetitive collaboration Chris Cain doi:10.1038/scibx.2012.483 Although pharmas are cutting back on internal neuroscience R&D programs, the number of precompetitive consortia backed by industry continues to rise. Most initiatives are focused on developing better disease models and discovering new biomarkers. The challenge going forward will be to push the boundaries of the precompetitive space to advance the discovery of new disease-modifying targets and mechanisms. Full Text | PDF
Mitochondrial gene therapy Lev Osherovich doi:10.1038/scibx.2012.484 A University of Miami team has used mitochondrion-targeted gene therapy to restore functional ND4 levels in Leber's hereditary optical neuropathy. Next steps include optimizing the approach to cover several variants of the disease and determining the therapy's potential advantages over pharmacological strategies in development. Full Text | PDF
PPAR's new course Steve Edelson doi:10.1038/scibx.2012.485 California researchers have shown that agonizing PPARδ could help stave off fibrosis in a variety of chronic liver diseases. The findings could open new therapeutic real estate for the handful of biotechs working on PPARδ modulators. Full Text | PDF
Dendrimers get cerebral Tim Fulmer doi:10.1038/scibx.2012.486 U.S. researchers have developed a dendrimer-based therapy that reduced brain inflammation and improved the motor function of newborn rabbits with cerebral palsy. The team now needs to determine the therapy's treatment window and its efficacy in the multiple types of cerebral palsy. Full Text | PDF
Dedicator of cytokinesis 2 (DOCK2) doi:10.1038/scibx.2012.487 In vitro and mouse studies identified a small molecule DOCK2 inhibitor that could help treat autoimmune disease. Full Text | PDF
MicroRNA-301a (miR-301a) doi:10.1038/scibx.2012.488 A study in mice suggests antagonizing miR-301a could help treat MS. Full Text | PDF
Hedgehog pathway; P glycoprotein (MDR1; ABCB1; P-gp; CD243) doi:10.1038/scibx.2012.489 Mouse studies suggest P-gp inhibitors could help reverse resistance to saridegib in medulloblastoma. Full Text | PDF
Autophagy doi:10.1038/scibx.2012.490 In vitro and mouse studies suggest dimeric chloroquine analogs could help treat cancer more effectively than hydroxychloroquine. Full Text | PDF
Glucose-6-phosphate dehydrogenase (G6PD) doi:10.1038/scibx.2012.491 An SAR study identified G6PD inhibitors that could be useful for treating solid tumors. Full Text | PDF
Tumor necrosis factor-α (TNF-α) doi:10.1038/scibx.2012.492 Mouse studies suggest low-dose, recombinant TNF-α could be useful as an adjuvant for cancer immunotherapy. Full Text | PDF
CD3; insulin (INS; proinsulin); IL-10 doi:10.1038/scibx.2012.493 Studies in mice suggest Lactococcus lactis engineered to secrete both IL-10 and proinsulin could help treat type 1 diabetes. Full Text | PDF
Peroxisome proliferation–activated receptor-δ (PPARD; PPARd) doi:10.1038/scibx.2012.494 Cell culture and mouse studies suggest PPARδ agonists could help treat liver fibrosis. Full Text | PDF
High mobility group box 1 (HMGB1); IL-1β; tumor necrosis factor-α (TNF-α) doi:10.1038/scibx.2012.495 Rat and cell culture studies identified gold complexes of 6-substituted purine derivatives that could help treat inflammation. Full Text | PDF
Peroxisome proliferation–activated receptor-γ (PPARG; PPARGγ) doi:10.1038/scibx.2012.496 Mouse studies suggest PPARγ inhibitor–treated human mesenchymal stem cells (MSCs) and MSC-derived extracellular matrix (ECM) could help repair bone. Full Text | PDF
D4Z4 binding element transcript (DBE-T) doi:10.1038/scibx.2012.497 Cell culture studies suggest inhibiting DBE-T could help treat facioscapulohumeral dystrophy (FSHD), which is a common autosomal-dominant type of muscular dystrophy. Full Text | PDF
MicroRNA-206 (miR-206) doi:10.1038/scibx.2012.498 Mouse studies suggest agonizing miR-206 could be useful for treating muscle injury and Duchenne muscular dystrophy (DMD). Full Text | PDF
Bromodomain containing 4 (BRD4) doi:10.1038/scibx.2012.500 An in vitro study suggests the epigenetic target BRD4 also has kinase activity, which could be inhibited to treat cancer or inflammation. Full Text | PDF
Aptamer-based assay against secreted proteins for the identification of new cancer biomarkers doi:10.1038/scibx.2012.501 An aptamer-based assay of secreted proteins may help identify new cancer biomarkers. Full Text | PDF
Paper-based assay for reporting blood type as text doi:10.1038/scibx.2012.502 A paper-based assay was used to identify and display blood type as text. Full Text | PDF
Algorithm for creating charged antibodies to improve stability and preserve activity doi:10.1038/scibx.2012.503 In silico and in vitro studies identified a strategy to create positively charged antibodies that have better stability and lower aggregation than unmodified counterparts. Full Text | PDF
Dopamine D2 receptor expression as a measure of Huntington's disease (HD) pathology doi:10.1038/scibx.2012.504 Measuring dopamine D2 receptor expression in mouse models of HD could aid the study of therapeutics to treat the disease. Full Text | PDF
Mice with working memory deficits as models of dementia-related delirium doi:10.1038/scibx.2012.505 Mice with short-term deficits in working memory could be useful models of dementia-related delirium and could aid the discovery of new treatments. Full Text | PDF
SH3 and multiple ankyrin repeat domains 2 (SHANK2)-deficient mouse model of autism spectrum disorder (ASD) doi:10.1038/scibx.2012.506 Mice lacking Shank2 could be used as models to study ASD and develop new treatments for the condition. Full Text | PDF
Acyclic cucurbit[n]urils as molecular containers to improve drug solubility doi:10.1038/scibx.2012.507 Acyclic cucurbit[n]uril compounds may be useful as molecular containers to increase the solubility of poorly soluble drugs. Full Text | PDF
Gene therapy for Leber's hereditary optical neuropathy (LHON) doi:10.1038/scibx.2012.508 Cell culture and mouse studies suggest a mitochondria-targeted transgene could be useful for treating LHON. Full Text | PDF
Epigenomic enhancer variants as biomarkers for colorectal cancer doi:10.1038/scibx.2012.509 In vitro studies identified epigenomic markers that could be used as biomarkers for colorectal cancer. Full Text | PDF
Genomic and expression analysis–derived breast cancer subgroups to predict response to therapy doi:10.1038/scibx.2012.510 Genomic and expression analysis–derived subgroups of breast cancer may help predict response to therapy. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment